Scientific Publications

The landmark research of BostonGene underscores the importance of combining innovative multi-platform analytics with cutting-edge software to improve patient outcomes. Explore our scientific publications to learn more.

  • 2022

A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity.

More
  • 2022

A classification system for urothelial carcinoma (UC) defined by genomic drivers and the tumor microenvironment (TME) is predictive of immunotherapy response.

More
  • 2021

Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma

More
  • 2021

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

More
  • 2021

The Combination of Duvelisib and Romidepsin (DR) Is Highly Active Against Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Final Results and Biomarker Analysis

More
  • 2021

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

More
  • 2021

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

More
  • 2021

HHV-6 in the Lymphoma Microenvironment: Both Chicken and Egg?

More
  • 2021

Immune-Depleted Tumor Microenvironment Signature Is Associated with BTK Inhibitor Resistance in Mantle Cell Lymphoma

More
  • 2021

A Prospective Study of Clonal Evolution in Follicular Lymphoma: Circulating Tumor DNA Correlates with Overall Tumor Burden and Fluctuates over Time without Therapy

More